U.S. District Court Denies Biogen Idec's Motion for Summary Judgment and Vacates Previous Ruling Regarding Corixa's BEXXAR Patents
Friday January 23, 6:30 am ET
SEATTLE--(BUSINESS WIRE)--Jan. 23, 2004--Corixa (Nasdaq:CRXA - News) announced today that the United States District Court, Southern District of California, has vacated its October 14, 2003 grant of Biogen Idec's motion for summary judgment in which BEXXAR® U.S. Patent Nos. 5,595,721; 6,015,542; 6,090,365 and 6,287,537 were held to be unenforceable due to a finding of inequitable conduct before the U.S. Patent and Trademark Office. Based on new evidence, as well as other evidence not previously considered, the Court has now vacated its previous order. Accordingly, the Court also denied Biogen Idec's motion for summary judgment of inequitable conduct.
"We are extremely pleased with the Court's decision," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "The Court's ruling is an important step in our efforts to enforce our patent position and intellectual property rights."
As a result of the Court's order, the previous ruling declaring Corixa's BEXXAR patents unenforceable has been reversed and the pending litigation regarding these patents will continue in the United States District Court, Southern District of California. Due to the Court's denial of Biogen Idec's motion for summary judgment, there will be no need for Corixa to file an appeal to the Federal Circuit... |
